33%

Faster Time to Insights

52%

Cost & Maintenance Savings

41%

Better Patient Decision-Making

67%

Increase in Sales Margins

Finding the right anti-epileptic drug (AED) is critical for improving patient outcomes and driving business success in the pharmaceutical industry. Up to 70% of epilepsy patients can achieve seizure control with the right medication, making drug effectiveness a key factor for both healthcare providers and pharma companies.

Our interactive dashboard enables pharma executives, R&D professionals, and healthcare strategists to compare long-acting (LA) vs. short-acting (SA) AED monotherapy in terms of healthcare utilization, patient adherence, and cost efficiency. By leveraging advanced data analytics for pharma, this solution helps businesses optimize drug strategies, improve market positioning, and accelerate data-driven decision-making.

Frequently asked questions

It compares drug options, such as long-acting versus short-acting AED monotherapy, on healthcare utilization, patient adherence, and cost efficiency, giving pharma executives evidence for market positioning decisions.

Up to 70% of epilepsy patients can achieve seizure control with the right medication, so comparing efficacy and adherence between drug formats directly affects both patient outcomes and which product a business prioritizes.

Pharma executives, R&D professionals, and healthcare strategists making decisions about drug positioning and market access strategy.

A drug that is more effective in trials but harder to adhere to in practice may perform worse in the real world; comparing both together avoids that blind spot.

Healthcare utilization and cost outcomes associated with each drug format, not just the drug’s list price, since downstream utilization often affects total cost more than acquisition cost.

By structuring utilization, adherence, and cost data into a BI platform through Business Analytics services, drawing on Life Sciences industry work.